FXS6837 not checked
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Dose 1 · Dose 2
FollowEvery change as it happens, and a Monday email
Trials
4 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “FXS6837 capsule orally taken according to protocol for 2 years”In the company’s words, NCT07750665 on ClinicalTrials.gov
- Tested for
- Paroxysmal Nocturnal Hemoglobinuria (2 trials), IgAN, Primary IgAN
- Main trialPhase 3
- “An open label study to evaluate the efficacy and safety of FXS6837 capsules compared to eculizumab in naive PNH patients. About 90 PNH patients who are naive to complement inhibitor therapies will be enrolled to take FXS6837 capsules or eculizumab for 24 weeks according to protocol.”In the company’s words, NCT07747090 on ClinicalTrials.gov
- Other names
- Dose 1 · Dose 2
Other drugs for Paroxysmal Nocturnal Hemoglobinuria
Coming up4
- 12 Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- 5 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 17 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 13 Nov 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 5 May 2028 | A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH. | |
| Phase 3Not yet recruiting | 17 May 2028 | A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients. | |
| Phase 2Not yet recruiting | 12 Sep 2027 | FXS6837 for the Treatment of IgAN Patients | |
| Phase 2Not yet recruiting | 13 Nov 2029 | FXS6837 for the Treatment for IgAN Patients(Longterm Study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026